Announces Closing of Previously Announced Public Offering

Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX) today reported that it has closed its previously announced public offering of shares of its common stock. The Company sold 16,428,572 shares of its common stock in the offering, which included 2,142,857 shares that were...

Announcing the Enrollment of a New Phase 2 Study for SMA

Catalyst Pharmaceuticals Announces Phase 2 Study of Firdapse® in Ambulatory Patients with Spinal Muscular Atrophy (SMA) Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people...